| scholarly article | Q13442814 |
| P50 | author | Tesfaye W Tefera | Q88095214 |
| Karin Borges | Q42409437 | ||
| P2093 | author name string | Karin Borges | |
| Tesfaye W Tefera | |||
| P2860 | cites work | Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice | Q21131923 |
| Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial | Q21245063 | ||
| A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis | Q21262053 | ||
| Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis | Q21266563 | ||
| Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1 | Q22299419 | ||
| Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain | Q22337252 | ||
| Ketogenic diet and other dietary treatments for epilepsy | Q24186154 | ||
| A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease | Q24816672 | ||
| The microglial-motoneuron dialogue in ALS | Q27000470 | ||
| Cerebral metabolism following traumatic brain injury: new discoveries with implications for treatment | Q27023017 | ||
| In Vivo imaging reveals distinct inflammatory activity of CNS microglia versus PNS macrophages in a mouse model for ALS | Q27349669 | ||
| Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
| Glutamate uptake | Q28190140 | ||
| From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS | Q28206361 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons | Q28298056 | ||
| Long-term acetyl-L-carnitine treatment in Alzheimer's disease | Q28333901 | ||
| Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis | Q28335672 | ||
| Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo | Q28364065 | ||
| Triheptanoin improves brain energy metabolism in patients with Huntington disease | Q28388261 | ||
| Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis | Q28482111 | ||
| Ketogenic diet improves forelimb motor function after spinal cord injury in rodents | Q28534800 | ||
| High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex | Q28578642 | ||
| ALS: a disease of motor neurons and their nonneuronal neighbors | Q29618000 | ||
| Onset and progression in inherited ALS determined by motor neurons and microglia | Q29619515 | ||
| Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization | Q29620724 | ||
| Mechanisms of ischemic neuroprotection by acetyl-L-carnitine | Q30389339 | ||
| Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. | Q30440341 | ||
| Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. | Q30494108 | ||
| Glycolysis and the significance of lactate in traumatic brain injury | Q30938714 | ||
| Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties | Q31621261 | ||
| Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. | Q33294971 | ||
| Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis | Q87384496 | ||
| Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? | Q38260277 | ||
| Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis | Q38366741 | ||
| AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis | Q38552413 | ||
| Cerebral Lactate Metabolism After Traumatic Brain Injury | Q38742790 | ||
| A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease | Q39110459 | ||
| Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis | Q39200143 | ||
| Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial | Q39344567 | ||
| A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. | Q39432513 | ||
| Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity | Q39492965 | ||
| Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. | Q40165089 | ||
| Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. | Q40368104 | ||
| Aerobic production and utilization of lactate satisfy increased energy demands upon neuronal activation in hippocampal slices and provide neuroprotection against oxidative stress | Q40385439 | ||
| A clinical trial of creatine in ALS. | Q40469445 | ||
| Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis | Q40723426 | ||
| Alpha-ketoglutarate and malate uptake and metabolism by synaptosomes: further evidence for an astrocyte-to-neuron metabolic shuttle | Q41593514 | ||
| Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease | Q41734464 | ||
| Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids | Q41945381 | ||
| Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency | Q42153700 | ||
| Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models | Q42409348 | ||
| Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis | Q42509201 | ||
| Lactate reduces glutamate-induced neurotoxicity in rat cortex | Q42514331 | ||
| Lowered cerebral glucose utilization in amyotrophic lateral sclerosis | Q42521169 | ||
| Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model | Q42749841 | ||
| Short- and medium-chain fatty acids in energy metabolism: the cellular perspective | Q42766173 | ||
| Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine | Q42966552 | ||
| Acetyl-L-carnitine reduces the infarct size and striatal glutamate outflow following focal cerebral ischemia in rats | Q42969544 | ||
| Lactate is always the end product of glycolysis | Q43166048 | ||
| The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. | Q43287637 | ||
| Neuroprotective role of lactate after cerebral ischemia | Q43292770 | ||
| Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease | Q43439006 | ||
| Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia | Q43548502 | ||
| Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. | Q43572865 | ||
| Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease | Q43669934 | ||
| The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones | Q43681257 | ||
| Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats | Q43793315 | ||
| Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients | Q43883813 | ||
| Lactate administration attenuates cognitive deficits following traumatic brain injury | Q43885977 | ||
| Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons | Q44105695 | ||
| Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis | Q44187182 | ||
| Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis | Q44205425 | ||
| A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 | ||
| Effect of lactate therapy upon cognitive deficits after traumatic brain injury in the rat. | Q44931184 | ||
| Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy | Q45181504 | ||
| Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? | Q45388639 | ||
| Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain | Q45840054 | ||
| Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer's disease. | Q46056482 | ||
| Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole | Q33529864 | ||
| Cognitive impairment following high fat diet consumption is associated with brain inflammation. | Q33665160 | ||
| Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms | Q33665291 | ||
| The effects of a ketogenic diet on behavioral outcome after controlled cortical impact injury in the juvenile and adult rat. | Q33744257 | ||
| Metabolic and histologic effects of sodium pyruvate treatment in the rat after cortical contusion injury | Q33767257 | ||
| Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1(G93A) mouse model of amyotrophic lateral sclerosis | Q33892886 | ||
| Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis | Q33906246 | ||
| Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases | Q33917550 | ||
| Oligodendroglia metabolically support axons and contribute to neurodegeneration. | Q34032818 | ||
| Neuroprotective effects of pyruvate following NMDA-mediated excitotoxic insults in hippocampal slices | Q34034916 | ||
| Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? | Q34088731 | ||
| Beneficial effects of sodium or ethyl pyruvate after traumatic brain injury in the rat | Q34126225 | ||
| Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis | Q34187004 | ||
| Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial | Q34251334 | ||
| Clinical pharmacology of the dietary supplement creatine monohydrate. | Q34253434 | ||
| Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis | Q34300016 | ||
| Sirtuins as therapeutic targets of ALS. | Q34357662 | ||
| Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death | Q34375696 | ||
| Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease | Q34474226 | ||
| Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target | Q34567689 | ||
| Energy intake and amyotrophic lateral sclerosis | Q34582888 | ||
| Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis | Q34627577 | ||
| Dexpramipexole is ineffective in two models of ALS related neurodegeneration | Q34744144 | ||
| Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain | Q34777969 | ||
| Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options | Q34815254 | ||
| Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo | Q34961411 | ||
| Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions | Q35086167 | ||
| Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis | Q35094527 | ||
| Ketogenic diet prevents alterations in brain metabolism in young but not adult rats after traumatic brain injury. | Q35212553 | ||
| Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement | Q35223033 | ||
| An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy. | Q35246605 | ||
| Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors | Q35684292 | ||
| Early and progressive impairment of spinal blood flow-glucose metabolism coupling in motor neuron degeneration of ALS model mice | Q35800499 | ||
| A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis | Q35822554 | ||
| D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease | Q35919815 | ||
| Endogenous Nutritive Support after Traumatic Brain Injury: Peripheral Lactate Production for Glucose Supply via Gluconeogenesis | Q35932745 | ||
| Lactate: brain fuel in human traumatic brain injury: a comparison with normal healthy control subjects. | Q35932802 | ||
| Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. | Q35948547 | ||
| Exogenous lactate infusion improved neurocognitive function of patients with mild traumatic brain injury | Q35983324 | ||
| Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral Sclerosis | Q36114275 | ||
| Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects | Q36225925 | ||
| A probable dual mode of action for both L- and D-lactate neuroprotection in cerebral ischemia | Q36267408 | ||
| Anaplerotic molecules: current and future | Q36501322 | ||
| The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. | Q36522329 | ||
| L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade. | Q36596141 | ||
| Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. | Q36677109 | ||
| Sodium pyruvate reduces hypoxic-ischemic injury to neonatal rat brain | Q36682284 | ||
| Lost in translation: treatment trials in the SOD1 mouse and in human ALS. | Q36735871 | ||
| Premorbid body mass index and risk of amyotrophic lateral sclerosis | Q36737158 | ||
| Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency | Q36859501 | ||
| MitoQ--a mitochondria-targeted antioxidant. | Q36887240 | ||
| High-Fat Diet Induced Anxiety and Anhedonia: Impact on Brain Homeostasis and Inflammation | Q36906680 | ||
| Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease | Q37093737 | ||
| KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. | Q37272764 | ||
| Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model | Q37285915 | ||
| Ketosis and brain handling of glutamate, glutamine, and GABA | Q37294731 | ||
| Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants | Q37352307 | ||
| Alterations of hippocampal glucose metabolism by even versus uneven medium chain triglycerides. | Q37459904 | ||
| Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. | Q37717433 | ||
| Energy metabolism in amyotrophic lateral sclerosis | Q37805077 | ||
| Mitochondrial dysfunction in ALS. | Q37914353 | ||
| The changing scene of amyotrophic lateral sclerosis | Q38086771 | ||
| ALS Untangled No. 20: the Deanna protocol | Q38103571 | ||
| Oligodendroglia: metabolic supporters of axons | Q38132499 | ||
| Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. | Q38195974 | ||
| Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial | Q46067965 | ||
| Ketogenic diet reduces cytochrome c release and cellular apoptosis following traumatic brain injury in juvenile rats. | Q46129124 | ||
| Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice | Q46254778 | ||
| Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. | Q46281670 | ||
| Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients | Q46354513 | ||
| Protection by exogenous pyruvate through a mechanism related to monocarboxylate transporters against cell death induced by hydrogen peroxide in cultured rat cortical neurons. | Q46386518 | ||
| Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology | Q46457932 | ||
| Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury | Q46492468 | ||
| Lactate: a major and crucial player in normal function of both muscle and brain | Q46565218 | ||
| Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window | Q46686089 | ||
| The neuroprotective effect of lactate is not due to improved glutamate uptake after controlled cortical impact in rats | Q47269521 | ||
| The protective effect of the ketogenic diet on traumatic brain injury-induced cell death in juvenile rats | Q47902341 | ||
| Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity | Q48098641 | ||
| Neuroprotective effects of lactate in brain ischemia: dependence on anesthetic drugs | Q48100624 | ||
| New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration | Q48115530 | ||
| Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS. | Q48121748 | ||
| D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo | Q48364448 | ||
| The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. | Q48378456 | ||
| Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease | Q48474459 | ||
| Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. | Q48513277 | ||
| Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study | Q48535842 | ||
| Pyruvate protects neurons against hydrogen peroxide-induced toxicity | Q48579857 | ||
| Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. | Q48582883 | ||
| Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. | Q48735249 | ||
| Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis | Q48881997 | ||
| Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease | Q49153506 | ||
| Neuroprotective effects of α-ketoglutarate and ethyl pyruvate against motor dysfunction and oxidative changes caused by repeated 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure in mice. | Q50861907 | ||
| Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. | Q51714635 | ||
| Hypermetabolism in ALS patients: an early and persistent phenomenon. | Q51755449 | ||
| Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. | Q53202071 | ||
| Acetyl-L-carnitineameliorates mitochondrial damage and apoptosis following spinal cord injury in rats. | Q53466722 | ||
| Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. | Q53582566 | ||
| Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 | ||
| Amyotrophic lateral sclerosis | Q55877676 | ||
| The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis | Q56773744 | ||
| Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients | Q56839377 | ||
| A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis | Q57666978 | ||
| Preclinical research: Make mouse studies work | Q59058234 | ||
| The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients | Q59901143 | ||
| Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models | Q60552719 | ||
| Triheptanoin in acute mouse seizure models | Q62785908 | ||
| Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosis | Q63410203 | ||
| Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study | Q68095604 | ||
| Acetyl-L-carnitine attenuates neuronal damage in gerbils with transient forebrain ischemia only when given before the insult | Q70921038 | ||
| A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group | Q72759362 | ||
| Avid Na+-dependent, high-affinity uptake of alpha-ketoglutarate by nerve terminal enriched material from mouse cerebellum | Q72888128 | ||
| Neuroprotective effects of acetyl-L-carnitine after stroke in rats | Q73396042 | ||
| Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis | Q74237337 | ||
| EFFECTS OF CARNITINE ON ACETYL-COA OXIDATION BY HEART MUSCLE MITOCHONDRIA | Q76846436 | ||
| Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model | Q83522395 | ||
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 611 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Frontiers in Neuroscience | Q2177807 |
| P1476 | title | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments | |
| P478 | volume | 10 |
| Q64230186 | Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis |
| Q97692894 | Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing |
| Q41032768 | Brugada syndrome in a patient with amyotrophic lateral sclerosis: a case report |
| Q33729341 | Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models |
| Q42377167 | Genetic induction of hypometabolism by ablation of MC4R does not suppress ALS-like phenotypes in the G93A mutant SOD1 mouse model. |
| Q50118955 | Lymphoblastoid cell lines as a model to understand amyotrophic lateral sclerosis disease mechanisms |
| Q89823775 | Medium Chain Triglycerides Modulate the Ketogenic Effect of a Metabolic Switch |
| Q60949835 | Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS |
| Q62785679 | Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q50091767 | Quantitative susceptibility mapping of the motor cortex: a comparison of susceptibility among patients with amyotrophic lateral sclerosis, cerebrovascular disease, and healthy controls |
| Q61817166 | Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease) |
Search more.